Drugs / IMV-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02507583 | Sep 2015 → Mar 2018 | malignant glioma | david andrews | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04485949 | Mar 2023 → Jan 2027 expected | glioblastoma | Imvax | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-08 | Imvax | Results Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022 imvax.com ↗
Preclinical findings presented at the meeting support the applicability of Imvax’s platform to hepatocellular carcinoma and ovarian and other gynecological cancers. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-04-08 | Imvax | Imvax Presents New Data on Tumor-Derived Immunotherapies in Glioblastoma, Other Solid Tumors at AACR Annual Meeting 2022 imvax.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMV-001 | “PURPOSE: Despite standard of care (SOC) established by Stupp, glioblastoma remains a uniformly poor prognosis. We evaluated IGV-001, which combines autologous glioblastoma...” PMID 33500356 ↗ Jan 20211“IGV-001, an immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers.” NCT04485949 ↗ |
| Action | Inhibit | “This treatment involves taking the patient's own tumor cells at surgery, treating them with an investigational new drug (an antisense molecule) designed to shut down a targeted...” NCT02507583 ↗ |
| Modality | Antisense oligonucleotide | “an antisense oligonucleotide against IGF type 1 receptor (IMV-001)” PMID 33500356 ↗ Jan 2021 |
| Route | Other | “Tumor cells collected during resection were treated ex vivo with IMV-001, encapsulated in biodiffusion chambers with additional IMV-001, irradiated, then implanted in abdominal...” PMID 33500356 ↗ Jan 2021 |
| Target | IGF1R | “an antisense oligonucleotide against IGF type 1 receptor (IMV-001)” PMID 33500356 ↗ Jan 2021 |